ClinicalTrials.gg
RecruitingNCT06010199FORWARDUpdated Nov 17, 2026

Clinical Phenotypes, Long-Term Outcomes, and Biobanking in Myocarditis

An observational study in Myocarditis, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.
Updated Nov 17, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Myocarditis with a site in China — 10 open to participants now, 10 under way, 1 of them phase 3. Myocarditis · China.

Planned enrollment
2nd of 10
5,000 · median 287
Started
2023
with 1 other
Observational
10 of 14
7 open now
Registered
5th of 14
by date
Lead sponsor
2 of 14
First Affiliated Hospital Xi'an Jiaotong University

Among the 14 studies in Myocarditis with a site in China, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2023, is one of 10 observational ones, and was the 5th registered.

Myocarditis

175 studies on the registry are indexed under Myocarditis; 75 are open to participants now.

Browse Myocarditis studies →

Open to participants now

10 of the 14 studies in Myocarditis with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 53 Myocarditis studies recruiting now, 32 (60%) set no upper age limit and 6 (11%) stop at 75 or younger; 15 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myocarditis with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to understand how myocarditis, an inflammation of the heart muscle, presents, changes over time, and affects long-term health in patients of all ages in China. The study also aims to build a collection of blood, other body fluids, and tissue samples linked to patients' medical information to support future research.

The main questions it aims to answer are:

  • How do symptoms, disease severity, treatment, and recovery differ among patients with myocarditis?
  • How often do patients experience death, heart transplantation, hospitalization for heart failure, or serious abnormal heart rhythms within one year, and how does their health change over five years? Researchers will compare patients with different symptoms, disease severity, stages of illness, and diagnostic findings. Treatment decisions remain with the patients' treating doctors.

This is an amendment to the ongoing FORWARD study, not a new study. The registry aims to include approximately 5,000 patients using both existing medical records and ongoing enrollment.

For patients taking part in prospective follow-up, participation will involve:

  • Allowing researchers to collect information from their usual medical care.
  • Providing health updates through routine visits, medical records, or telephone contact over an observation period generally lasting five years.
  • Optionally allowing additional blood or other body fluid samples to be collected during an already needed clinical sampling procedure, or allowing tissue remaining after clinical and diagnostic needs have been met to be used for research.

No extra clinic visits, tests, or needle insertions are required solely for this study. Sample collection depends on clinical opportunities, patient safety, and consent. Patients may participate in the clinical registry and follow-up without providing samples.

Read the detailed description

FORWARD is an ongoing, investigator-initiated, nationwide multicenter observational registry cohort study of patients with myocarditis in China. This registration update reflects an amendment to the existing study registered as NCT06010199. The amendment refines the study's scope, eligibility, retrospective coverage, prospective recruitment, follow-up, and biospecimen resource development. Previously enrolled participants retain their original study identifiers and observation timelines. New or modified research activities will be implemented following applicable ethics approval.

The objectives are to characterize clinical phenotypes, diagnostic findings, treatment patterns, disease course, and long-term outcomes, and to develop a traceable biospecimen resource linked to longitudinal clinical information. The platform will support future clinical and translational research. Specific subsequent projects will require separate protocols and applicable approvals, identify FORWARD as the source of their data and samples, and remain within the relevant consent and authorization scope.

Study population and design

Patients of all ages and sexes with myocarditis diagnosed by qualified treating physicians at participating centers are eligible, subject to the protocol criteria. Recruitment includes outpatient, inpatient, and intensive care settings, including patients receiving mechanical circulatory support or heart transplantation. First episodes, recurrent disease, persistent disease, and recovery phases may be included.

Diagnosis is based on clinical assessment and available laboratory, electrocardiographic, imaging, and, when clinically obtained, histopathological findings, with reference to guidelines and diagnostic standards applicable to the patient's age and period of care. Cardiac magnetic resonance imaging and endomyocardial biopsy are not mandatory for every participant, and no diagnostic procedure is performed solely to establish research eligibility. Updates to diagnostic standards will be documented, while original diagnoses and supporting records will be preserved.

The study combines retrospective and prospective components. Retrospective coverage extends from January 1, 2003, through the protocol amendment date. Prospective recruitment will continue through December 31, 2045. The target registry size is approximately 5,000 unique patients, including eligible previously enrolled, retrospectively identified, and newly recruited participants. This target is a resource-development goal rather than a fixed recruitment cap. Repeated encounters, recurrent episodes, and repeated samples are linked to the same participant identifier.

No treatment is assigned by the study. Medications, investigations, procedures, mechanical circulatory support, and transplantation are determined independently by treating clinicians.

Clinical data and observation periods

Clinical data include demographics, symptom onset, diagnosis and diagnostic evidence, clinical presentation, disease severity, comorbidities, laboratory results, electrocardiography, cardiac imaging, available pathology, treatments, and clinical events. Dates of symptom onset, diagnosis, registry entry, and sample collection are recorded separately.

The clinical baseline is generally the first qualifying encounter or hospitalization within the observation period. Core follow-up assessments are scheduled at 1, 3, 6, and 12 months and annually during years 2 through 5. Information is obtained through routine care visits, hospital records, existing medical records, and telephone contact. Hospitalized patients also have information recorded during admission and at discharge. Study-specific visits or additional clinical investigations are not required.

Historical outcomes are reconstructed from available records without creating retrospective visits. Participants whose original five-year observation period is incomplete may continue for the remaining period. For historical patients whose five-year observation period has already ended, a separate five-year prospective observation phase may begin at registry entry after the applicable consent process. Historical and newly initiated prospective observation periods are recorded and analyzed separately. Existing observation periods are not restarted by the amendment. New prospective observation phases will generally begin by December 31, 2045, with scheduled follow-up completed by December 31, 2050.

Outcomes and comparisons

The primary outcome is the first occurrence of a composite of all-cause death, heart transplantation, hospitalization for heart failure, or serious ventricular arrhythmia within one year after the clinical baseline. Serious ventricular arrhythmia includes sustained ventricular tachycardia, ventricular fibrillation, or resuscitated arrhythmic cardiac arrest. Sustained ventricular tachycardia is defined as lasting at least 30 seconds or requiring earlier termination because of hemodynamic instability. Individual components are also reported.

For participants with a hospitalization-based baseline, the index hospitalization does not count as a heart failure hospitalization outcome. Other qualifying events occurring after baseline during that admission remain eligible. Subsequent hospitalization for new or worsening heart failure is counted, and continuous transfers are treated as a single hospitalization. For an outpatient baseline, the first subsequent hospitalization for new or worsening heart failure is eligible.

Secondary outcomes include the specified clinical events at 30 days, 90 days, six months, and years 2 through 5; recurrent hospitalizations; use and duration of mechanical circulatory support; myocarditis recurrence; changes in cardiac function and structure; functional status; and other arrhythmias or conduction abnormalities. Registry performance measures include data completeness, follow-up completion, biospecimen availability, longitudinal sample coverage, and sample quality.

Comparisons are observational and based on clinical presentation, disease severity, episode status, disease phase, diagnostic evidence, age, sex, comorbidities, center, and period of care. Clinical presentations include chest pain, heart failure, arrhythmia, mixed presentations, and other or minimally symptomatic presentations. These strata do not determine treatment.

Optional biospecimen collection

Biospecimens may be obtained at baseline and any follow-up time point when a suitable clinical sampling opportunity exists and the applicable consent has been obtained. Blood and other body fluids are collected as additional research aliquots during the same sampling procedure already required for clinical care. Research blood is additional blood collected at that time, not leftover blood from clinical testing. No separate research-only puncture or additional sampling procedure is performed.

Patient safety, clinical needs, and participant preferences take priority. Treating clinicians determine whether collection is appropriate and the amount that can safely be obtained, considering age, body weight, clinical condition, recent cumulative sampling, and willingness to participate. There is no mandatory minimum sample volume. Tissue is limited to material remaining after clinical care and pathological diagnostic requirements have been met; no additional biopsy or extension of surgery is performed for research.

Previously stored samples may be used only after verification of their source, storage records, and applicable authorization or ethics approval. Lack of samples, insufficient sample volume, or refusal of sample collection does not prevent enrollment or continued clinical follow-up. Sample timing, type, quantity, disease status, treatment context, and processing information are linked to clinical records using coded identifiers.

Consent, data quality, and analysis

Retrospective data and previously stored samples are used within applicable consent or ethics-approved waiver arrangements. Prospective participants complete the applicable consent process. For eligible adults participating only in clinical registration and noninvasive follow-up without any research biospecimen use, a waiver of consent signature may be used only where specifically approved; explicit oral consent and approved process documentation remain required. Other participants follow the applicable written consent procedures. Minors require guardian consent and age-appropriate involvement in the decision, with confirmation by the participant upon reaching adulthood.

Data and samples are managed using unique identifiers, restricted access, standardized definitions, and quality checks. Analyses will describe clinical characteristics and outcomes and evaluate associations while considering confounding, center effects, and changes in diagnostic practice over time. Time-to-event, competing-risk, recurrent-event, and longitudinal methods will be used as appropriate. Historical observation and separately initiated prospective observation will be analyzed separately. The platform protocol does not include development of prediction models.

03

Conditions studied

  • Myocarditis

Browse trials for

Keywords

  • Myocarditis
  • Risk stratification
  • Biobanking
  • Clinical Phenotypes
  • Long-Term Outcomes
  • Retrospective and Prospective Cohort
  • Translational Research
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients of all ages and sexes with physician-diagnosed myocarditis receiving routine care at the First Affiliated Hospital of Xi'an Jiaotong University and other FORWARD centers in China. Sources include outpatient clinics, inpatient wards, intensive care units, and services providing mechanical circulatory support or heart transplantation. The population includes retrospectively identified patients with qualifying encounters from January 1, 2003, through the protocol amendment date, eligible previously enrolled participants, and patients recruited prospectively through December 31, 2045. First episodes, recurrent disease, persistent disease, and recovery phases are eligible. Patients may participate without providing biospecimens or attending additional in-person visits. Retrospectively identified patients who subsequently undergo prospective follow-up retain their original cohort assignment and unique identifier.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of any age and sex with myocarditis diagnosed by a qualified treating physician at a participating center. Diagnosis is based on clinical assessment and available laboratory, electrocardiographic, imaging, and, when clinically obtained, histopathological evidence, with reference to guidelines and age-appropriate diagnostic standards applicable at the time of care.
  • Patients with a first episode, recurrent myocarditis, persistent disease, or a recovery-phase presentation. For patients with a historical diagnosis or a recovery-phase presentation, the original diagnosis must be supported by verifiable clinical documentation. Comorbid conditions do not preclude inclusion when myocarditis is independently supported.
  • Patients identified retrospectively from qualifying clinical encounters between January 1, 2003, and the protocol amendment date; patients previously enrolled in FORWARD who remain eligible under the amended protocol; or eligible patients newly enrolled prospectively after the amendment becomes effective through December 31, 2045. Previously enrolled participants retain their original identifiers and are not enrolled again.
  • Availability of sufficient core information to verify participant identity, baseline age, the qualifying clinical encounter date, and the clinical diagnosis of myocarditis.
  • Completion of the applicable or ethics-approved waiver process. Prospective participants provide written informed consent unless they qualify for an explicitly approved waiver of consent signature. That pathway is limited to adults aged 18 years or older who can independently provide informed consent, participate only in clinical registration and noninvasive follow-up, and do not participate in any research biospecimen collection, use, or testing; explicit oral consent and approved documentation remain required. Minors require guardian written consent and age-appropriate involvement in the decision. Participants temporarily lacking consent capacity follow the approved representative-consent process. Retrospective inclusion must fall within applicable consent or ethics-approved waiver arrangements.

Exclusion criteria

Exclusion Criteria:

  • Myocarditis cannot be verified after review of available clinical documentation, or clinical reassessment establishes that the original diagnosis is not supported and another condition adequately explains the presentation. An unverified diagnostic code, self-reported history, or an isolated abnormal test result is insufficient for inclusion.
  • Essential information required to confirm eligibility remains unavailable after reasonable efforts to obtain it, including participant identity, the qualifying clinical encounter date, or documentation supporting the myocarditis diagnosis.
  • The participant or appropriate legally authorized representative explicitly refuses clinical registry participation, or valid consent cannot be obtained and no applicable ethics-approved alternative process is available. Retrospective records or samples outside the approved consent, waiver, or authorized use scope are not eligible for the corresponding research activities.
  • Other specifically documented circumstances that establish failure to meet the protocol inclusion criteria.

Additional Eligibility Clarifications:

  • Cardiac magnetic resonance imaging and endomyocardial are not mandatory for every participant. No diagnostic procedure is required solely for research eligibility.
  • Changes in guidelines or diagnostic classifications, or the absence of investigations that were not routinely available during historical care, do not automatically invalidate an existing enrollment. Original diagnostic records are retained, and any reassessment is documented.
  • Advanced age, minority, critical illness, comorbidities, pregnancy, breastfeeding, or inability to attend regular in-person visits does not independently exclude a patient from the clinical registry.
  • Providing biospecimens is optional. Refusal, lack of a clinical sampling opportunity, safety concerns, insufficient sample volume, or failure to obtain a sample does not exclude a participant or terminate clinical follow-up.
  • Partial missing laboratory, imaging, or follow-up information does not independently exclude an otherwise eligible participant. Missing information and its reasons are documented.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    Patients of all ages with physician-diagnosed myocarditis identified retrospectively from clinical records covering January 1, 2003, through the protocol amendment date. Available diagnostic, treatment, and outcome data will be collected from existing records. Historical outcomes will be reconstructed for up to five years after the qualifying clinical baseline. Patients may continue the remaining observation period or, after completing the historical period and the applicable consent process, begin a separate five-year prospective observation phase. They retain their original cohort assignment and unique identifier. Historical and newly initiated observation periods are recorded and analyzed separately. Previously stored samples may be used within applicable authorization and ethics approval. Sample availability is not required for inclusion. No treatment is assigned by the study.

  • Prospective Cohort

    Patients of all ages with physician-diagnosed myocarditis enrolled prospectively in the existing FORWARD study or newly recruited through December 31, 2045, excluding those assigned to the retrospective cohort. Previously enrolled patients retain their original identifiers and observation timelines. Clinical data and outcomes are collected at baseline, during hospitalization when applicable, at 1, 3, 6, and 12 months, and annually during years 2 through 5, using routine visits, medical records, or telephone contact. Treatment remains determined by treating clinicians. Optional additional blood or other body fluids may be collected during clinically required sampling, with applicable consent and safety assessment; tissue is limited to material remaining after clinical and pathological needs are met. No research-only puncture is performed. Lack of samples does not affect enrollment or follow-up.

06

What researchers measure

Primary outcomes

  1. One-Year Cumulative Probability of All-Cause Death, Heart Transplantation, Heart Failure Hospitalization, or Serious Ventricular Arrhythmia

    Cumulative probability of the first occurrence of all-cause death, heart transplantation, hospitalization for new or worsening heart failure, or serious ventricular arrhythmia within one year after the qualifying clinical baseline. Serious ventricular arrhythmia includes sustained ventricular tachycardia, ventricular fibrillation, or resuscitated arrhythmic cardiac arrest. Sustained ventricular tachycardia lasts at least 30 seconds or requires earlier termination because of hemodynamic instability. The index hospitalization is excluded only from the heart failure hospitalization component; other qualifying events after baseline during that admission are included. Continuous hospital transfers count as one admission. Each component is also reported separately. Outcomes from a separately initiated prospective observation phase are not pooled with historical baseline outcomes.

    Time frame: From the qualifying clinical baseline through 1 year

Secondary outcomes

  1. Cumulative Probability of the Composite Clinical Outcome at Short- and Long-Term Follow-Up

    Cumulative probability of the first occurrence of all-cause death, heart transplantation, hospitalization for new or worsening heart failure, or serious ventricular arrhythmia, using the same definitions as the primary outcome. Each component is reported separately. The timing and total number of recurrent heart failure hospitalizations are also recorded. The index hospitalization is excluded only from the heart failure hospitalization component, and continuous hospital transfers count as one admission. Events before the applicable observation start are recorded as history rather than new outcomes. Historical observation and any separately initiated prospective observation phase are analyzed separately.

    Time frame: At 30 days, 90 days, 6 months, and 2, 3, 4, and 5 years after the applicable observation start

  2. Cumulative Probability of All-Cause Death

    Cumulative probability, expressed as a percentage, of death from any cause. Death dates are ascertained from available medical records and follow-up information.

    Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start

  3. Cumulative Incidence of Heart Transplantation

    Cumulative incidence, expressed as a percentage, of the first heart transplantation after the applicable observation start, verified from clinical records. Death before transplantation is treated as a competing event.

    Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start

  4. Cumulative Incidence of First Heart Failure Hospitalization

    Cumulative incidence, expressed as a percentage, of the first hospitalization for new or worsening heart failure. For an inpatient baseline, the index admission is excluded. For an outpatient baseline, the first subsequent qualifying admission is included. Continuous hospital transfers count as one admission. Death before a qualifying hospitalization is treated as a competing event.

    Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start

  5. At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start

    Cumulative incidence, expressed as a percentage, of the first documented episode of sustained ventricular tachycardia, ventricular fibrillation, or resuscitated arrhythmic cardiac arrest after the applicable observation start. Event definitions are the same as for the primary outcome. Death before a qualifying arrhythmia is treated as a competing event.

    Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start

  6. Number of Heart Failure Hospitalizations per Participant

    Number of qualifying hospitalizations for new or worsening heart failure per participant during the observed period, including the first qualifying admission and subsequent admissions. For an inpatient baseline, the index admission is excluded. Continuous hospital transfers count as one admission.

    Time frame: From the applicable observation start through 5 years

  7. Cumulative Incidence of First Myocarditis Recurrence

    Cumulative incidence, expressed as a percentage, of the first physician-confirmed recurrence of myocarditis after the applicable observation start. Recurrence requires new clinical manifestations with supporting objective evidence documented in routine care. Persistent symptoms or an isolated abnormal test result alone do not establish recurrence. Death before recurrence is treated as a competing event.

    Time frame: From the applicable observation start through 5 years

  8. Number of Myocarditis Recurrences per Participant

    Number of distinct physician-confirmed recurrent myocarditis episodes per participant during the observed period. Each episode requires new clinical manifestations with supporting objective evidence. Repeated records referring to the same episode are counted once.

    Time frame: From the applicable observation start through 5 years

  9. Change From Baseline in Left Ventricular Ejection Fraction

    Change in left ventricular ejection fraction, expressed in percentage points, calculated as the follow-up value minus the baseline value. Paired values are obtained from clinically indicated cardiac imaging using comparable measurement methods.

    Time frame: Baseline and 1, 3, 6, and 12 months and years 2, 3, 4, and 5 after the applicable observation start, when clinically available

  10. Percentage of Participants Receiving Mechanical Circulatory Support

    Percentage of participants who receive mechanical circulatory support at least once during the applicable observation period, based on routine clinical records. Support already in use at the observation start is included if it continues into the observation period. Each participant is counted once regardless of the number of support episodes.

    Time frame: From the applicable observation start through 5 years

  11. Duration of Mechanical Circulatory Support per Episode

    Duration of mechanical circulatory support, in days per episode, measured from documented initiation to discontinuation. Duration is summarized for episodes with verifiable start and end dates. Episodes still ongoing at the last observation are not treated as completed episodes.

    Time frame: For support episodes observed from the applicable observation start through 5 years

  12. Percentage of Participants With Other Arrhythmias

    Percentage of participants with at least one documented new or recurrent arrhythmia other than the serious ventricular arrhythmias included in the primary outcome. Events are identified from clinically obtained electrocardiograms, rhythm monitoring, and medical records. A pre-existing arrhythmia without a documented new episode is not counted as an event.

    Time frame: From the applicable observation start through 5 years

  13. Percentage of Participants With Newly Documented Conduction Abnormalities

    Percentage of participants with at least one conduction abnormality newly documented during the observation period, based on clinically obtained electrocardiograms or rhythm monitoring. An abnormality already documented at the applicable observation start is not counted as newly documented.

    Time frame: From the applicable observation start through 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2046, 280 months after the start.

Of 70 non-industry observational studies under Myocarditis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 251. This study's planned 280 months is above that.

Counting every sponsor, half of 72 studies reached it within 69 months; a quarter within 22 and three quarters within 251.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2030 → Dec 2046 and completion Aug 2030 → Dec 2050.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Aug 24, 2023
StartActual
Aug 25, 2023
Primary completionEst.
Dec 31, 2046was Jul 2030
CompletionEst.
Dec 31, 2050was Aug 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2030→Dec 31, 2046
Nov 17, 2026
Study completion
Aug 31, 2030→Dec 31, 2050
Nov 17, 2026
Enrollment
1000→5000
Nov 17, 2026
Eligibility
Minimum age 3 Years→none; Maximum age 80 Years→none; Criteria largely rewritten (21 changes)
What changed in the criteria
Inclusion criteria
  • RemovedAll patients should meet the diagnostic criteria for myocarditis
  • RemovedPatients who are regularly followed up at the corresponding cardiovascular center
  • AddedPatients of any age and sex with myocarditis diagnosed by a qualified treating physician at a participating center. Diagnosis is based on clinical assessment and available laboratory, electrocardiographic, imaging, and, when clinically obtained, histopathological evidence, with reference to guidelines and age-appropriate diagnostic standards applicable at the time of care.
  • AddedPatients with a first episode, recurrent myocarditis, persistent disease, or a recovery-phase presentation. For patients with a historical diagnosis or a recovery-phase presentation, the original diagnosis must be supported by verifiable clinical documentation. Comorbid conditions do not preclude inclusion when myocarditis is independently supported.
  • AddedPatients identified retrospectively from qualifying clinical encounters between January 1, 2003, and the protocol amendment date; patients previously enrolled in FORWARD who remain eligible under the amended protocol; or eligible patients newly enrolled prospectively after the amendment becomes effective through December 31, 2045. Previously enrolled participants retain their original identifiers and are not enrolled again.
  • AddedAvailability of sufficient core information to verify participant identity, baseline age, the qualifying clinical encounter date, and the clinical diagnosis of myocarditis.
  • AddedCompletion of the applicable informed consent or ethics-approved waiver process. Prospective participants provide written informed consent unless they qualify for an explicitly approved waiver of consent signature. That pathway is limited to adults aged 18 years or older who can independently provide informed consent, participate only in clinical registration and noninvasive follow-up, and do not participate in any research biospecimen collection, use, or testing; explicit oral consent and approved documentation remain required. Minors require guardian written consent and age-appropriate involvement in the decision. Participants temporarily lacking consent capacity follow the approved representative-consent process. Retrospective inclusion must fall within applicable consent or ethics-approved waiver arrangements.
Exclusion criteria
  • RemovedAge <3 years or >80 years
  • RemovedPregnant or lactating women
  • RemovedThe patient refused to sign the informed consent and refused to participate in the study
  • RemovedNone of the above is consistent, but the patient cannot sign the informed consent temporarily due to coma and other reasons, and there is no legal representative to sign it instead. Depending on the condition, the patient may not wake up to sign the informed consent
  • AddedMyocarditis cannot be verified after review of available clinical documentation, or clinical reassessment establishes that the original diagnosis is not supported and another condition adequately explains the presentation. An unverified diagnostic code, self-reported history, or an isolated abnormal test result is insufficient for inclusion.
  • AddedEssential information required to confirm eligibility remains unavailable after reasonable efforts to obtain it, including participant identity, the qualifying clinical encounter date, or documentation supporting the myocarditis diagnosis.
  • AddedThe participant or appropriate legally authorized representative explicitly refuses clinical registry participation, or valid consent cannot be obtained and no applicable ethics-approved alternative process is available. Retrospective records or samples outside the approved consent, waiver, or authorized use scope are not eligible for the corresponding research activities.
  • AddedOther specifically documented circumstances that establish failure to meet the protocol inclusion criteria.
  • AddedAdditional Eligibility Clarifications:
  • AddedCardiac magnetic resonance imaging and endomyocardial biopsy are not mandatory for every participant. No diagnostic procedure is required solely for research eligibility.
  • AddedChanges in guidelines or diagnostic classifications, or the absence of investigations that were not routinely available during historical care, do not automatically invalidate an existing enrollment. Original diagnostic records are retained, and any reassessment is documented.
  • AddedAdvanced age, minority, critical illness, comorbidities, pregnancy, breastfeeding, or inability to attend regular in-person visits does not independently exclude a patient from the clinical registry.
  • AddedProviding biospecimens is optional. Refusal, lack of a clinical sampling opportunity, safety concerns, insufficient sample volume, or failure to obtain a sample does not exclude a participant or terminate clinical follow-up.
  • AddedPartial missing laboratory, imaging, or follow-up information does not independently exclude an otherwise eligible participant. Missing information and its reasons are documented.
Nov 17, 2026
Interventions
Arms added: Retrospective Cohort·Prospective Cohort; arms removed: Myocarditis group
Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in the incidence of MACCENow One-Year Cumulative Probability of All-Cause Death, Heart Transplantation, Heart Failure Hospitalization, or Serious Ventricular ArrhythmiaTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment. → From the qualifying clinical baseline through 1 year
Nov 17, 2026
Secondary outcomes
1 edited, 12 added, 3 removed
What changed in the outcomes
  • EditedChange in the incidenceCumulative Probability of allAll-cause deathCause DeathTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment. → At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
  • AddedCumulative Probability of the Composite Clinical Outcome at Short- and Long-Term Follow-UpTime frame: At 30 days, 90 days, 6 months, and 2, 3, 4, and 5 years after the applicable observation start
  • AddedCumulative Incidence of Heart TransplantationTime frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
  • AddedCumulative Incidence of First Heart Failure HospitalizationTime frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
  • AddedAt 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation startTime frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
  • AddedNumber of Heart Failure Hospitalizations per ParticipantTime frame: From the applicable observation start through 5 years
  • AddedCumulative Incidence of First Myocarditis RecurrenceTime frame: From the applicable observation start through 5 years
  • AddedNumber of Myocarditis Recurrences per ParticipantTime frame: From the applicable observation start through 5 years
  • AddedChange From Baseline in Left Ventricular Ejection FractionTime frame: Baseline and 1, 3, 6, and 12 months and years 2, 3, 4, and 5 after the applicable observation start, when clinically available
  • AddedPercentage of Participants Receiving Mechanical Circulatory SupportTime frame: From the applicable observation start through 5 years
  • AddedDuration of Mechanical Circulatory Support per EpisodeTime frame: For support episodes observed from the applicable observation start through 5 years
  • AddedPercentage of Participants With Other ArrhythmiasTime frame: From the applicable observation start through 5 years
  • AddedPercentage of Participants With Newly Documented Conduction AbnormalitiesTime frame: From the applicable observation start through 5 years
  • RemovedChange in the incidence of myocardial infarctionTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.
  • RemovedChange in the incidence of strokeTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.
  • RemovedChange in the incidence of coronary revascularization surgeryTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.
Nov 17, 2026
Contact
Study contact's phone or email changed: •••2523→•••3868; l•••@163.com→g•••@xjtu.edu.cn; •••2601→•••3865. See the current contact
Nov 17, 2026
Title
Risk Stratification Value of Biomarkers in Patients With Myocarditis→Clinical Phenotypes, Long-Term Outcomes, and Biobanking in Myocarditis
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Jul 31, 2030→Dec 31, 2046
    Study completion Aug 31, 2030→Dec 31, 2050
    Enrollment 1000→5000
    Eligibility Minimum age 3 Years→none; Maximum age 80 Years→none; Criteria largely rewritten (21 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedAll patients should meet the diagnostic criteria for myocarditis
    • RemovedPatients who are regularly followed up at the corresponding cardiovascular center
    • AddedPatients of any age and sex with myocarditis diagnosed by a qualified treating physician at a participating center. Diagnosis is based on clinical assessment and available laboratory, electrocardiographic, imaging, and, when clinically obtained, histopathological evidence, with reference to guidelines and age-appropriate diagnostic standards applicable at the time of care.
    • AddedPatients with a first episode, recurrent myocarditis, persistent disease, or a recovery-phase presentation. For patients with a historical diagnosis or a recovery-phase presentation, the original diagnosis must be supported by verifiable clinical documentation. Comorbid conditions do not preclude inclusion when myocarditis is independently supported.
    • AddedPatients identified retrospectively from qualifying clinical encounters between January 1, 2003, and the protocol amendment date; patients previously enrolled in FORWARD who remain eligible under the amended protocol; or eligible patients newly enrolled prospectively after the amendment becomes effective through December 31, 2045. Previously enrolled participants retain their original identifiers and are not enrolled again.
    • AddedAvailability of sufficient core information to verify participant identity, baseline age, the qualifying clinical encounter date, and the clinical diagnosis of myocarditis.
    • AddedCompletion of the applicable informed consent or ethics-approved waiver process. Prospective participants provide written informed consent unless they qualify for an explicitly approved waiver of consent signature. That pathway is limited to adults aged 18 years or older who can independently provide informed consent, participate only in clinical registration and noninvasive follow-up, and do not participate in any research biospecimen collection, use, or testing; explicit oral consent and approved documentation remain required. Minors require guardian written consent and age-appropriate involvement in the decision. Participants temporarily lacking consent capacity follow the approved representative-consent process. Retrospective inclusion must fall within applicable consent or ethics-approved waiver arrangements.
    Exclusion criteria
    • RemovedAge <3 years or >80 years
    • RemovedPregnant or lactating women
    • RemovedThe patient refused to sign the informed consent and refused to participate in the study
    • RemovedNone of the above is consistent, but the patient cannot sign the informed consent temporarily due to coma and other reasons, and there is no legal representative to sign it instead. Depending on the condition, the patient may not wake up to sign the informed consent
    • AddedMyocarditis cannot be verified after review of available clinical documentation, or clinical reassessment establishes that the original diagnosis is not supported and another condition adequately explains the presentation. An unverified diagnostic code, self-reported history, or an isolated abnormal test result is insufficient for inclusion.
    • AddedEssential information required to confirm eligibility remains unavailable after reasonable efforts to obtain it, including participant identity, the qualifying clinical encounter date, or documentation supporting the myocarditis diagnosis.
    • AddedThe participant or appropriate legally authorized representative explicitly refuses clinical registry participation, or valid consent cannot be obtained and no applicable ethics-approved alternative process is available. Retrospective records or samples outside the approved consent, waiver, or authorized use scope are not eligible for the corresponding research activities.
    • AddedOther specifically documented circumstances that establish failure to meet the protocol inclusion criteria.
    • AddedAdditional Eligibility Clarifications:
    • AddedCardiac magnetic resonance imaging and endomyocardial biopsy are not mandatory for every participant. No diagnostic procedure is required solely for research eligibility.
    • AddedChanges in guidelines or diagnostic classifications, or the absence of investigations that were not routinely available during historical care, do not automatically invalidate an existing enrollment. Original diagnostic records are retained, and any reassessment is documented.
    • AddedAdvanced age, minority, critical illness, comorbidities, pregnancy, breastfeeding, or inability to attend regular in-person visits does not independently exclude a patient from the clinical registry.
    • AddedProviding biospecimens is optional. Refusal, lack of a clinical sampling opportunity, safety concerns, insufficient sample volume, or failure to obtain a sample does not exclude a participant or terminate clinical follow-up.
    • AddedPartial missing laboratory, imaging, or follow-up information does not independently exclude an otherwise eligible participant. Missing information and its reasons are documented.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in the incidence of MACCENow One-Year Cumulative Probability of All-Cause Death, Heart Transplantation, Heart Failure Hospitalization, or Serious Ventricular ArrhythmiaTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment. → From the qualifying clinical baseline through 1 year
    Secondary outcomes 1 edited, 12 added, 3 removed
    What changed in the outcomes
    • EditedChange in the incidenceCumulative Probability of allAll-cause deathCause DeathTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment. → At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
    • AddedCumulative Probability of the Composite Clinical Outcome at Short- and Long-Term Follow-UpTime frame: At 30 days, 90 days, 6 months, and 2, 3, 4, and 5 years after the applicable observation start
    • AddedCumulative Incidence of Heart TransplantationTime frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
    • AddedCumulative Incidence of First Heart Failure HospitalizationTime frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
    • AddedAt 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation startTime frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
    • AddedNumber of Heart Failure Hospitalizations per ParticipantTime frame: From the applicable observation start through 5 years
    • AddedCumulative Incidence of First Myocarditis RecurrenceTime frame: From the applicable observation start through 5 years
    • AddedNumber of Myocarditis Recurrences per ParticipantTime frame: From the applicable observation start through 5 years
    • AddedChange From Baseline in Left Ventricular Ejection FractionTime frame: Baseline and 1, 3, 6, and 12 months and years 2, 3, 4, and 5 after the applicable observation start, when clinically available
    • AddedPercentage of Participants Receiving Mechanical Circulatory SupportTime frame: From the applicable observation start through 5 years
    • AddedDuration of Mechanical Circulatory Support per EpisodeTime frame: For support episodes observed from the applicable observation start through 5 years
    • AddedPercentage of Participants With Other ArrhythmiasTime frame: From the applicable observation start through 5 years
    • AddedPercentage of Participants With Newly Documented Conduction AbnormalitiesTime frame: From the applicable observation start through 5 years
    • RemovedChange in the incidence of myocardial infarctionTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.
    • RemovedChange in the incidence of strokeTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.
    • RemovedChange in the incidence of coronary revascularization surgeryTime frame: 1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.
    Interventions Arms added: Retrospective Cohort·Prospective Cohort; arms removed: Myocarditis group
    Contact Study contact's phone or email changed: •••2523→•••3868; l•••@163.com→g•••@xjtu.edu.cn; •••2601→•••3865. See the current contact
    Title Risk Stratification Value of Biomarkers in Patients With Myocarditis→Clinical Phenotypes, Long-Term Outcomes, and Biobanking in Myocarditis
    + 4 other changes: verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06010199
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Aug 25, 2023
Primary completion
Dec 31, 2046 (estimated)
Completion
Dec 31, 2050 (estimated)
Last update
Nov 17, 2026

Study contacts

Guoliang Li
Contact
guoliangli@xjtu.edu.cn
0086-2985323868
Yang Yan
Contact
yangyan3@xjtu.edu.cn
+862985323865
Yang Yan
principal investigator · First Affiliated Hospital Xi'an Jiaotong University
Guoliang Li
principal investigator · First Affiliated Hospital Xi'an Jiaotong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion